FGF21 and obesity due to melanocortin 4 receptor deficiency: In preclinical studies, FGF21 lowered plasma insulin, triglycerides, liver fat,and body weight [6], which led to high expectations for a novel, efficacious treatment for obesity, type 2 diabetes, dyslipidemia, and MASH [7].